Company intelligence / Profile preview

Mengyang Pharmaceutical

Jingmen, Hubei, China

Ownership: Private
Employees: ~200
Development stage: Other

Overview

The company's lead asset, DH-001, has reached Phase 2 clinical trials for reducing adriamycin (doxorubicin)-induced cardiotoxicity. Other pipeline programs include pre-clinical therapies for chemotherapy-induced thrombocytopenia and acute radiation sickness. There are also several marketed or late-stage traditional Chinese medicine products (Shengbai Oral Liquid, Polyporus Capsule, etc.) for leukopenia and immune enhancement.

Therapeutic areas: ImmunologyGastroenterologyInfectious DiseasesCardiovascularHematology
Modalities: Small moleculeBiologic (biological preparations, but specifics unclear)
Industry: Biotech

Drug pipeline

2 assets

Shengbai oral liquid

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Mengyang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mengyang Pharmaceutical.

Explore the full profile